Medical Advocates
Enfuvirtide [T-20] (Fuzeon)
 
Pediatric Indications

US Treatment Guidelines
Safety/Tolerability
 Pharmacokinetics
Efficacy


 
Enfuvirtide Main Page Main New/Newsworthy Home Page nbsp;    
Last Update:  May 29, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Read
Safety/Tolerability
 

Journal Papers, Abstracts, and Commentaries

 
Long Term Tolerability and Safety of Enfuvirtide for Human Immunodeficiency Virus 1
-Infected Children.
 Pediatric AIDS Clinical Trials Group P1005 Study Team.  
Pediatr Infect Dis J. 2004 Aug;23(8):713-718.
 Abstract


Conference Reports, Abstracts, and Commentaries

 
The role of enfuvirtide (T-20) in multiresistant congenital HIV disease treated since birth
Manfredi R., Calza L., Chiodo F.
 (3rd IAS)
 Abstract
 
24-Week Safety and Efficacy of Enfuvirtide as Part of an Optimized ART Regimen
in Children
 A  Wiznia, J Church , P Emmanuel, et a1
(12  CROI)
 Abstract

Chronic Subcutaneous T-20 in HIV-1 Infected Children: Safety and Anti-Viral Activity  
 C Cunningham , J. Church, P. Palumbo, et al
(41 ICAAC)
 Abstract
 
  Safety and Antiviral Activity of Chronic Subcutaneous Administration of T-20 in HIV-1-
Infected Children
J Church, C Cunningham, P Palumbo, et al.
 (8 CROI)
Abstract
Pharmacokinetics
 

Journal Papers, Abstracts, and Commentaries

  Pharmacokinetics of Enfuvirtide in Pediatric Human Immunodeficiency Virus 1-Infected
Patients Receiving Combination Therapy.
 Bellibas SE, Siddique Z, Dorr A  
Pediatr Infect Dis J. 2004 Dec;23(12):1137-1141
 Abstract
 
Population pharmacokinetics of enfuvirtide in pediatric patients with human
immunodeficiency virus: searching for exposure-response relationships.
 Soy D, Aweeka FT, Church JA, et al. 
Clin Pharmacol Ther. 2003 Dec;74(6):569-80.
 Abstract

Conference Reports, Abstracts, and Commentaries

  Pharmacokinetics (PK) of Selected Doses of T-20, a Fusion Inhibitor, in HIV-1- Infected
Children.
 B Kosel, J Church, C Cunningham, et al
 (8 CROI)
 Abstract
Efficacy
 
Pediatric Guidelines and Recommendations
 
  USPHS Pediatric Antiretroviral Drug Information
 (Effective March 24, 2005) 
 Fusion Inhibitor Data
Enfuvirtide Data

 
24-Week Safety and Efficacy of Enfuvirtide as Part of an Optimized ART Regimen
in Children
 A  Wiznia, J Church , P Emmanuel, et a1
 (12  CROI)
 Abstract
 
POSTER
24-week Safety and Efficacy of Enfuvirtide as Part of an Optimized Antiretroviral
Regimen in Adolescents
A Wiznia, J Church, J Stavola, et al
 (11 CROI)
 PDF Poster    Abstract

Enfuvirtide Main Page Main New/Newsworthy Home Page      

Enfuvirtide Pediatric Data